ArticleTranslational vision science & technology2025
Aquaporin-4 Peptide Injection in Mice Induces Retinal and Optic Nerve Alterations That Simulate Those of Neuromyelitis Optica Spectrum Disorder.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.Translational vision science & technology · 2026Article
- Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica.The Journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate functional and structural changes in the retinas and optic nerves of mice immunized with an aquaporin-4 (AQP4) peptide, which was previously shown to induce paralysis mimicking human neuromyelitis optica spectrum disorder (NMOSD). Methods: Electroretinography and histological analyses were used to evaluate retinal function, and inflammatory cell infiltration or glial fibrillary acidic protein immunoreactivity in the retinas and optic nerves of AQP4-immunized mice. Additionally, the blood-retinal barrier function was assessed by Evans blue dye injection to measure in vivo retinal vascular permeability and by in vitro transendothelial electrical resistance using mouse primary retinal microvascular endothelial cells exposed to serum from AQP4-immunized mice. Results: AQP4 immunization led to a significant reduction in b-wave and scotopic threshold response amplitudes, indicating impaired inner retinal function. Histological analysis revealed inflammatory cell infiltration at the optic nerve head. Whole-mounted retinal glial fibrillary acidic protein immunoreactivity showed aberrant Müller cell activation, particularly in the juxtapapillary region. AQP4-immunized mice exhibited increased retinal Evans blue dye leakage and mouse retinal microvascular endothelial cells exhibited reduced transendothelial electrical resistance, indicating blood-retinal barrier disruption. Conclusions: AQP4 immunization induced functional impairment, inflammatory cell infiltration, glial cell activation, and blood-retinal barrier disruption in the retinas and optic nerves in mice, which mimics human NMOSD-associated optic neuritis. Translational Relevance: Along with the previously reported development of paralysis, this study indicates that AQP4 peptide-immunized mice can be considered an animal model of NMOSD and a powerful tool for further understanding the pathophysiology of NMOSD-associated optic neuritis and for assessing the efficacy of drugs in its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.